RE: Technicals7 Jul 2025 11:18
Key benefits from the research include improved diagnostic accuracy, better identification of patients likely to benefit from P140 therapy, and enhanced monitoring of treatment responses.
The results point to progress towards personalised medicine for systemic lupus erythematosus (SLE) and other autoimmune diseases, ImmuPharma told investors.
Update on this from earlier in the year along with a potential partnership will really put a rocket up the SP, although as Peterpharma has correctly stated we need this to see significant upward movement in the SP - all holders are acutely aware of this fact